SFA
BMRN icon

Sequoia Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sequoia Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$732K Buy
12,796
+5,305
+71% +$291K ﹤0.01% 1091
2026
Q1 		$423K Buy
7,491
+3,307
+79% +$193K ﹤0.01% 1368
2025
Q4 		$249K Sell
4,184
-2,470
-37% -$134K ﹤0.01% 1677
2025
Q3 		$360K Buy
+6,654
New +$381K ﹤0.01% 1302
2024
Q4 		– Sell
-3,967
Closed -$279K – 1365
2024
Q3 		$279K Buy
+3,967
New +$332K ﹤0.01% 1003

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sequoia Financial Advisors's BMRN Position: Q2 2026 in Review

Sequoia Financial Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 71% in Q2 2026, buying an estimated $291K and bringing the position to 12,796 shares worth $732K. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

Sequoia Financial Advisors first reported a position in BMRN in Q3 2024 and has held it in 5 quarters since. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Sequoia Financial Advisors held 12,796 shares of BioMarin Pharmaceuticals worth $732K as of Q2 2026.
  • Sequoia Financial Advisors bought 5,305 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $291K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Sequoia Financial Advisors's portfolio in Q2 2026, its #1091 holding.
  • Sequoia Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sequoia Financial Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.